Drug Profile
AES 005
Alternative Names: AES-005; AVI-005Latest Information Update: 19 May 2009
Price :
$50
*
At a glance
- Originator Synageva BioPharma
- Class Antivirals; Interferons
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Infections
Most Recent Events
- 19 May 2009 Discontinued - Phase-I for Infections in USA (SC)
- 30 Sep 2008 AES 005 is available for licensing and/or co-development in the USA (http://www.synageva.com)
- 30 Jun 2005 AVI 005 is available for partnering (http://www.avigenics.com)